Page 4 - Single Agent News Today

Share this article Share this article ResearchAndMarkets.coms offering. Endpoint security has become an important building block of a mature cybersecurity framework. Its significance has increased during the ongoing COVID-19 pandemic as enterprises have had to shift their entire employee bases to work from home during the nationwide lockdown. Cybercriminals have identified security gaps in endpoints and started exploiting devices with a motive to steal data and user credentials. Ransomware and ...

Merck known as MSD outside the United States and Canada, today announced the company is voluntarily withdrawing the U.S. indication for KEYTRUDA for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The withdrawal of this indication was done in consultation with the U.S. Food and Drug … Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announ...

Seagen Inc. (Nasdaq:SGEN) today announced that the European Commission (EC) has granted marketing authorization for TUKYSA ® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens. TUKYSA is an oral, small molecule tyrosine kinase inhibitor (TKI) of HER2, a protein that contributes to cancer cell growth. 1,2 “This approval...

KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib First Results From Pivotal CLEAR Study Presented at 2021 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine … KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Deat...

Published: Feb 12, 2021 European Commission Approves Seagen’s TUKYSA ® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer - Approved for Adult Patients with HER2-Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Anti-HER2 Treatment Regimens - - First HER-2 Tyrosine Kinase Inhibitor Combination Regimen to Improve Overall and Progression-Free Survival in Previously Treated Patients with Metastatic HER2-Positive Bre...

(2) - Recommendation for Approval in the European Union Based on Results of Pivotal HER2CLIMB Trial - Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending the approval of TUKYSA (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 p...